ProfileOfResearchers

TITLE: Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1 L) maintenance with or without second-line (2 L) treatment: Exploratory analyses from JAVELIN Bladder 100 Full Text
AUTHORS: Bellmunt, Joaquim; Powles, Thomas; Duran, Miguel A. Climent; Sridhar, Srikala S.; Gurney, Howard; Pook, David W.; Costa, Nuno; Di Pietro, Alessandra; Huang, Bo; Gupta, Shilpa; Grivas, Petros;
PUBLISHED: 2022, SOURCE: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 18

INDEXED IN:

WOS

TITLE: Avelumab first-line (1 L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1 L chemotherapy Full Text
AUTHORS: Valderrama, Begona P.; Powles, Thomas; Sridhar, Srikala S.; Caserta, Claudia; Loriot, Yohann; Gupta, Shilpa; Bellmunt, Joaquim; Sternberg, Cora N.; Pook, David W.; Wang, Jing; Costa, Nuno; Laliberte, Robert J.; di Pietro, Alessandra; Park, Se Hoon; Grivas, Petros;
PUBLISHED: 2022, SOURCE: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 18

INDEXED IN:

WOS

TITLE: Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naive Metastatic Clear-Cell Renal Cell Carcinoma Full Text
AUTHORS: Bedke, J; Albiges, L; Capitanio, U; Giles, RH; Hora, M; Lam, TB; Ljungberg, B; Marconi, L; Klatte, T; Volpe, A; Abu Ghanem, Y; Dabestani, S; Fernandez Pello, S; Hofmann, F; Kuusk, T; Tahbaz, R; Powles, T; Bex, A;
PUBLISHED: 2021, SOURCE: EUROPEAN UROLOGY, VOLUME: 79, ISSUE: 3

INDEXED IN:

Scopus

WOS

TITLE: Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.
AUTHORS: Loriot, Y; Powles, T; Duran, MAC; Sridhar, SS; Bellmunt, J; Petrylak, DP; Wang, J; Costa, NM; Laliberte, RJ; Di Pietro, A; Grivas, P; Sternberg, CN;
PUBLISHED: 2021, SOURCE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 39, ISSUE: 6

INDEXED IN:

WOS

TITLE: Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy? Full Text
AUTHORS: Abu Ghanem, Y; Powles, T; Capitanio, U; Beisland, C; Jarvinen, P; Stewart, GD; Gudmundsson, E; Lam, TBL; Marconi, L; Fernandez Pello, S; Nisen, H; Meijer, RP; Volpe, A; Ljungberg, B; Klatte, T; Bensalah, K; Dabestani, S; Bex, A;
PUBLISHED: 2021, SOURCE: BJU INTERNATIONAL

INDEXED IN:

Scopus

WOS

TITLE: Avelumab first-line maintenance for advanced urothelial carcinoma in the phase 3 JAVELIN Bladder 100 trial: subgroup analysis by duration of treatment-free interval from end of chemotherapy to start of maintenance Full Text
AUTHORS: Pook, D; Sridhar, S; Powles, T; Loriot, Y; Duran, MC; Gupta, S; Tsuchiya, N; Bamias, A; Ardizzoni, A; Ullen, A; Huang, B; Costa, N; Laliberte, R; di Pietro, A; Sternberg, C; Grivas, P;
PUBLISHED: 2021, SOURCE: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 17

INDEXED IN:

WOS

TITLE: Avelumab first-line maintenance plus best supportive care vs best supportive care alone for advanced urothelial carcinoma: JAVELIN Bladder 100 subgroup analysis based on duration and cycles of first-line chemotherapy Full Text
AUTHORS: Gurney, H; Loriot, Y; Powles, T; Duran, MC; Sridhar, S; Bellmunt, J; Petrylak, D; Wang, J; Costa, N; Laliberte, R; Di Pietro, A; Grivas, P; Sternberg, C;
PUBLISHED: 2021, SOURCE: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 17

INDEXED IN:

WOS

TITLE: Avelumab first-line maintenance for advanced urothelial carcinoma (aUC) in the phase 3 JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval from end of chemotherapy to start of maintenance Full Text
AUTHORS: Pook, DW; Sridhar, SS; Powles, T; Loriot, Y; Duran, MAC; Gupta, S; Tsuchiya, N; Bamias, A; Ardizzoni, A; Ullen, A; Huang, B; Costa, N; Laliberte, RJ; di Pietro, A; Sternberg, CN; Grivas, P;
PUBLISHED: 2021, SOURCE: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 17

INDEXED IN:

WOS

TITLE: Avelumab first-line maintenance plus best supportive care vs best supportive care alone for advanced urothelial carcinoma: JAVELIN Bladder 100 subgroup analysis based on duration and cycles of first-line chemotherapy Full Text
AUTHORS: Powles, T; Loriot, Y; Duran, MAC; Sridhar, S; Bellmunt, J; Petrylak, DP; Wang, J; Costa, N; Laliberte, R; di Pietro, A; Grivas, P; Sternberg, CN;
PUBLISHED: 2021, SOURCE: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 17

INDEXED IN:

WOS

TITLE: Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.
AUTHORS: Sridhar, SS; Powles, T; Loriot, Y; Duran, MAC; Gupta, S; Tsuchiya, N; Bamias, A; Ardizzoni, A; Ullen, A; Huang, B; Costa, NM; Laliberte, RJ; Di Pietro, A; Sternberg, CN; Grivas, P;
PUBLISHED: 2021, SOURCE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 39, ISSUE: 15

INDEXED IN:

WOS

Page 2 of 4. Total results: 39.

Useful Links